Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.

"Potential conflicts of interest. J. J. W., R. A. M., and M. F. are Takeda employees and stockholders. N. E. B. is a paid consultant for Takeda. S. A. reports research grants or contracts paid to institution from BioMérieux, Biotest, Elitech, Hologic, Merck, Merck Sharp & Dohme, and Takeda; honoraria for lectures paid to institution from Biotest, Merck Sharp & Dohme France, and Takeda; support for attending meetings from Biotest, Merck Sharp & Dohme France; advisory board paid to institution from Biotest, Merck Sharp & Dohme, and Takeda; and primary investigator for Solstice 303 study in France. C. C. reports consulting fees from Merck and Takeda; honoraria for lectures from Avir Pharma and Takeda; and advisory board membership for Takeda. R. F. C. reports consultancy fees from Merck/MSD, Oxford Immunotec, Takeda, and Viracor-Eurofins. C. N. K. reports paid consultant/clinical trial adjudication, honoraria for lectures, meeting support, and expert testimony for Takeda. J. L. reports research grants from the Danish Government, Danish National Research Foundation, and National Institutes of Allergy and Infectious Diseases. G. A. P. has received partial funding from P30 CA008748 Cancer Center Support Grant; and consulting fees from AlloVir, Cidara, Octapharma, Takeda, MSK, Symbio, and Vera Armatta; research funding paid to the institution from MSD and Takeda; and honoraria from MSD. M. R. P. reports consulting fees from Union Therapeutics; honoraria for presentations from Takeda; and advisory board membership for Takeda. All other authors report no potential conflicts.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Financial support . This work was supported by Takeda Development Center Americas, Inc., Lexington, MA; National Institutes of Health (grant number R01-AI116635 to S. C.); and use of US Department of Veterans Affairs facilities and resources. Funding to pay the Open Access publication charges for this article was provided by Takeda Development Center Americas, Inc., Lexington, MA. Financial support"

"Clinical Trials Registration NCT02931539."